Navigation Links
ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Date:9/1/2015

EDISON, N.J., Sept. 1, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Rodman & Renshaw 17th Annual Global Investment Conference sponsored by H.C. Wainwright & Co. taking place September 8-10, 2015 at The St. Regis Hotel in New York, NY.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Rodman & Renshaw 17th Annual Global Investment ConferenceDate: Thursday, September 10, 2015Time: 3:00pm (Eastern Time)Location:The St. Regis Hotel, New York, NYThe presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the investor relations section of the ContraVir website at www.contravir.com/ctrv.

About ContraVir Pharmaceuticals ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), for the Hepatitis B virus (HBV) in Phase 2 clinical studies.  CMX157 is active against HBV and more than 4 times more potent in vitro versus tenofovir.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  

For further information, please contact:Tiberend Strategic Advisors, Inc.

Tirth Patel (investors) 
tpatel@tiberend.com; (212) 375-2681

Claire Sojda (media) 
csojda@tiberend.com; (212) 375-2686

 

 

 


'/>"/>
SOURCE ContraVir Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. ContraVir to Present at Cavendish Global Health Impact Forum
2. MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations
3. Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting
4. VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015
5. Asterias Biotherapeutics to Present at Upcoming Investor Conferences
6. Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease
7. Roka Bioscience to Present at the Sidoti & Company Emerging Growth Conference
8. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
9. Asymmetrex Presents Its Crowdsourcing Campaign for Counting Adult Tissue Stem Cells at the 8th International Epigenetics, Stem Cells, Sequencing & SNiPs Meeting in August
10. Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
11. United Therapeutics Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/7/2020)... ... July 06, 2020 , ... ... from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, ... has hosted an elite awards program, highlighting outstanding examples of how technology innovations ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading ... Space™ for businesses of all types to ensure cleanliness, distancing and occupancy with its ... A Safe Space™ enabled business will provide a health performance index system that scores ...
(Date:6/23/2020)... ... , ... Kerafast Inc. , developers of an online ... of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by ... entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment. , ...
Breaking Biology Technology:
(Date:6/23/2020)... TORONTO (PRWEB) , ... June 22, 2020 , ... The ... time. Typically, ligand binding assays (LBA) have dominated this area. However, the use of ... several years. , This now necessitates the question “How do you choose which approach ...
(Date:6/23/2020)... ... 2020 , ... In its June 22 online post, business and technology news ... M.D., Ph.D., founder and director of stem cell biotechnology company Asymmetrex . Superb ... that starting July 5 it would begin offering free tissue stem cell counting ...
(Date:6/19/2020)... ... June 18, 2020 , ... Biosero ... Data Decisions,” for pharmaceutical and biotech executives, laboratory managers, scientists, researchers and ... instruments and laboratory equipment from dozens of manufacturers into their lab. , ...
Breaking Biology News(10 mins):